The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Pfizer is approaching a whole new era of growth after launching a record number of new products and putting a focus on its ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...